Trial Outcomes & Findings for A Randomized Control Trial Assessing the Effect of Topical Tranexamic Acid on Risk of Hematoma in Breast Surgery (NCT NCT05441592)

NCT ID: NCT05441592

Last Updated: 2025-11-26

Results Overview

Results reflect the number of hematomas that occurred during the trial, requiring operative washout or aspiration in participants who received TXA versus participants who did not receive TXA.

Recruitment status

COMPLETED

Study phase

PHASE4

Target enrollment

107 participants

Primary outcome timeframe

Up to approximately 4 weeks after surgery

Results posted on

2025-11-26

Participant Flow

Participant milestones

Participant milestones
Measure
Irrigation that contains tranexamic acid (TXA)
Tranexamic acid injection: The breast pockets will additionally be irrigated with 150 cc of 2.67% TXA (75 cc in each breast). The TXA solution will be allowed to be sit in the breast pocket for 15 minutes and then removed after 15 minutes.
No additional irrigation usual care
No additional irrigation: There will be no additional irrigation after the standard surgical procedure.
Overall Study
STARTED
55
52
Overall Study
COMPLETED
54
47
Overall Study
NOT COMPLETED
1
5

Reasons for withdrawal

Reasons for withdrawal
Measure
Irrigation that contains tranexamic acid (TXA)
Tranexamic acid injection: The breast pockets will additionally be irrigated with 150 cc of 2.67% TXA (75 cc in each breast). The TXA solution will be allowed to be sit in the breast pocket for 15 minutes and then removed after 15 minutes.
No additional irrigation usual care
No additional irrigation: There will be no additional irrigation after the standard surgical procedure.
Overall Study
Lost to Follow-up
1
5

Baseline Characteristics

A Randomized Control Trial Assessing the Effect of Topical Tranexamic Acid on Risk of Hematoma in Breast Surgery

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Irrigation That Contains Tranexamic Acid (TXA)
n=55 Participants
Tranexamic acid injection: The breast pockets will additionally be irrigated with 150 cc of 2.67% TXA (75 cc in each breast). The TXA solution will be allowed to be sit in the breast pocket for 15 minutes and then removed after 15 minutes.
No Additional Irrigation Usual Care
n=52 Participants
No additional irrigation: There will be no additional irrigation after the standard surgical procedure.
Total
n=107 Participants
Total of all reporting groups
Age, Continuous
24 years
n=492 Participants
28 years
n=492 Participants
26 years
n=984 Participants
Sex/Gender, Customized
Female
7 Participants
n=492 Participants
16 Participants
n=492 Participants
23 Participants
n=984 Participants
Sex/Gender, Customized
Male
0 Participants
n=492 Participants
0 Participants
n=492 Participants
0 Participants
n=984 Participants
Sex/Gender, Customized
Transgender Female
0 Participants
n=492 Participants
0 Participants
n=492 Participants
0 Participants
n=984 Participants
Sex/Gender, Customized
Transgender Male
34 Participants
n=492 Participants
25 Participants
n=492 Participants
59 Participants
n=984 Participants
Sex/Gender, Customized
Non-Binary
14 Participants
n=492 Participants
11 Participants
n=492 Participants
25 Participants
n=984 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
5 Participants
n=492 Participants
2 Participants
n=492 Participants
7 Participants
n=984 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
49 Participants
n=492 Participants
49 Participants
n=492 Participants
98 Participants
n=984 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
1 Participants
n=492 Participants
1 Participants
n=492 Participants
2 Participants
n=984 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=492 Participants
0 Participants
n=492 Participants
0 Participants
n=984 Participants
Race (NIH/OMB)
Asian
1 Participants
n=492 Participants
0 Participants
n=492 Participants
1 Participants
n=984 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=492 Participants
0 Participants
n=492 Participants
0 Participants
n=984 Participants
Race (NIH/OMB)
Black or African American
4 Participants
n=492 Participants
5 Participants
n=492 Participants
9 Participants
n=984 Participants
Race (NIH/OMB)
White
43 Participants
n=492 Participants
41 Participants
n=492 Participants
84 Participants
n=984 Participants
Race (NIH/OMB)
More than one race
4 Participants
n=492 Participants
1 Participants
n=492 Participants
5 Participants
n=984 Participants
Race (NIH/OMB)
Unknown or Not Reported
3 Participants
n=492 Participants
5 Participants
n=492 Participants
8 Participants
n=984 Participants
Region of Enrollment
United States
55 Participants
n=492 Participants
52 Participants
n=492 Participants
107 Participants
n=984 Participants

PRIMARY outcome

Timeframe: Up to approximately 4 weeks after surgery

Results reflect the number of hematomas that occurred during the trial, requiring operative washout or aspiration in participants who received TXA versus participants who did not receive TXA.

Outcome measures

Outcome measures
Measure
Irrigation that contains tranexamic acid (TXA)
n=54 Participants
Tranexamic acid injection: The breast pockets will additionally be irrigated with 150 cc of 2.67% TXA (75 cc in each breast). The TXA solution will be allowed to be sit in the breast pocket for 15 minutes and then removed after 15 minutes.
No additional irrigation usual care
n=47 Participants
No additional irrigation: There will be no additional irrigation after the standard surgical procedure.
Hematomas
0 hematomas
1 hematomas

SECONDARY outcome

Timeframe: Up to approximately 4 weeks after surgery

Results reflect the number of participants who experienced any major thromboembolic event during the trial. Major thromboembolic events included, but were not limited to, deep vein thrombosis, pulmonary embolism, and stroke.

Outcome measures

Outcome measures
Measure
Irrigation that contains tranexamic acid (TXA)
n=54 Participants
Tranexamic acid injection: The breast pockets will additionally be irrigated with 150 cc of 2.67% TXA (75 cc in each breast). The TXA solution will be allowed to be sit in the breast pocket for 15 minutes and then removed after 15 minutes.
No additional irrigation usual care
n=47 Participants
No additional irrigation: There will be no additional irrigation after the standard surgical procedure.
Participants Who Experienced a Major Thromboembolic Event Related to the Study Drug
0 Participants
0 Participants

SECONDARY outcome

Timeframe: Up to approximately 4 weeks after surgery

Results reflect the number of participants who experienced any major complication other than a hematoma. Major complications included, but were not limited to, infection, seroma, hypersensitivity reaction to TXA, and renal impairment.

Outcome measures

Outcome measures
Measure
Irrigation that contains tranexamic acid (TXA)
n=54 Participants
Tranexamic acid injection: The breast pockets will additionally be irrigated with 150 cc of 2.67% TXA (75 cc in each breast). The TXA solution will be allowed to be sit in the breast pocket for 15 minutes and then removed after 15 minutes.
No additional irrigation usual care
n=47 Participants
No additional irrigation: There will be no additional irrigation after the standard surgical procedure.
Participants Who Experienced Major Complications Other Than Hematoma
0 Participants
2 Participants

Adverse Events

Irrigation that contains tranexamic acid (TXA)

Serious events: 0 serious events
Other events: 6 other events
Deaths: 0 deaths

No additional irrigation usual care

Serious events: 1 serious events
Other events: 6 other events
Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure
Irrigation that contains tranexamic acid (TXA)
n=55 participants at risk
Tranexamic acid injection: The breast pockets will additionally be irrigated with 150 cc of 2.67% TXA (75 cc in each breast). The TXA solution will be allowed to be sit in the breast pocket for 15 minutes and then removed after 15 minutes.
No additional irrigation usual care
n=52 participants at risk
No additional irrigation: There will be no additional irrigation after the standard surgical procedure.
Blood and lymphatic system disorders
Hematoma Requiring Reoperation
0.00%
0/55 • 4 weeks
1.9%
1/52 • 4 weeks

Other adverse events

Other adverse events
Measure
Irrigation that contains tranexamic acid (TXA)
n=55 participants at risk
Tranexamic acid injection: The breast pockets will additionally be irrigated with 150 cc of 2.67% TXA (75 cc in each breast). The TXA solution will be allowed to be sit in the breast pocket for 15 minutes and then removed after 15 minutes.
No additional irrigation usual care
n=52 participants at risk
No additional irrigation: There will be no additional irrigation after the standard surgical procedure.
Infections and infestations
Surgical site infection
0.00%
0/55 • 4 weeks
3.8%
2/52 • 4 weeks
Injury, poisoning and procedural complications
Delayed wound healing
7.3%
4/55 • 4 weeks
9.6%
5/52 • 4 weeks
Skin and subcutaneous tissue disorders
Rash/Dermatitis
5.5%
3/55 • 4 weeks
1.9%
1/52 • 4 weeks

Additional Information

Edwin Wilkins

University of Michigan

Phone: 734-936-6680

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place